A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center Hospital East
Taiho Oncology, Inc.
Astellas Pharma Inc
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Astellas Pharma Inc
Vejle Hospital
Arcus Biosciences, Inc.
Children's Oncology Group
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Pfizer
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Akeso
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Seagen Inc.
Children's Oncology Group
Astellas Pharma Inc
OncoSil Medical Limited
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Duke University
FBD Biologics Limited
University of California, Irvine
Georgetown University
Dana-Farber Cancer Institute
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
University Hospital, Akershus
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
AbbVie
Revolution Medicines, Inc.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
University Health Network, Toronto